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easured glomerular filtration rate (mGFR) mea-
surement is necessary in specific patients and/or
specific clinical contexts.1–3 Plasma clearances are the
preferred methods, as they are less costly and
cumbersome than urinary clearances.4 The contrast
medium iohexol is the most commonly used world-
wide, partly for pragmatic reasons, as this marker is
stable, not radioactive, and its measurement is easy,
with the possibility of an external quality control.1,4,5
One goal of the European Kidney Function Con-
sortium (EKFC) is to increase the standardization of GFR
measurements. Recently, members of the EKFC have
compared plasma versus urinary clearances,6,7 single
versus multiple-sample plasma clearances,5,8 and the
different equations used in multiple-sample methods to
model the first (or early) compartment.9 The plasma
clearance is calculated by dividing the amount of
iohexol injected by the area under the curve obtained
from concentrations at single or multiple times (equa-
tions are given in Supplementary Table S1). Comparing
the plasma iohexol clearance methods used by different
centers, we realized that the amount of injected iohexol
was determined differently. Indeed, some centers
weighed the syringe of iohexol before and after injec-
tion, with the aim to determine the injected dose more
correctly than by calculating the theoretically injected
volume. When the density of iohexol is known (1.28
for Omnipaque 240 mgI/ml and 1.35 for Omnipaque
300 mgI/ml), the amount of iohexol (in micrograms
[mg]) is then easily calculated. As an example, 5 ml ofOmnipaque 240 mgI/ml corresponds to the following
calculated dose: (weight of syringe before  weight of
syringe after)  518/1.28  1000. The final dose of
iohexol is thus dependent on the difference of weights
before and after injection. Other centers considered
only the theoretical volume of injection. As an
example, if 5 ml of iohexol 240 or 300 mgI/ml is
injected, the amount of iohexol (in micrograms) is as
follows: 5  518  1000 and 5  647  1000, respec-
tively (518 and 647 being the quantity of iohexol [in
milligrams] in each milliliter of Omnipaque 240 and
300, respectively). With this method, the dose of
iohexol is fixed. The weight of the injected dose can be
obtained from the difference in weight of the syringe
before and after injection (¼ actual weight) or can be
calculated from the injected volume (¼ volume 
density). The distribution of the differences in weight
from both strategies was centered around zero, and
98.4% (¼ 4492/4565) were within [0.5; þ0.5 g]
(Supplementary Figure S1). In our quest to standardize
the iohexol plasma clearance procedure, we investi-
gated the potential differences induced by weighing
the syringes (GFRW) and using iohexol density or by
considering the theoretical injected volume (GFRV).
Such a comparison was possible in 3 large cohorts
(methods are described in detail in the Supplementary
Methods).
Among the 4565 participants, the median age was 53
(percentile [Pct] 25¼ 48; Pct 75 ¼ 62) years, the median
body mass index (BMI) was 25.7 (Pct 25 ¼ 22.6; PctKidney International Reports (2021) 6, 2478–2480
RESEARCH LETTER75 ¼ 29.1) kg/m2, and 46% of the participants were
female. The GFR was obtained with the multiple-
sample (MS) method in 2941 subjects. For these sub-
jects, the mean GFRW and GFRV were 63.56  26.24
and 63.80  26.35 ml/min, respectively. The median
paired difference between GFRW and GFRV was 0.06
(Pct 2.5 ¼ 3.48; Pct 97.5 ¼ 2.13) ml/min. A concor-
dance within 5% was observed in 96.6% of subjects.
The GFR obtained with the single-sample (SS) method
was available at time 180 minutes and 240 minutes in
4488 and 3018 subjects, respectively. With the SS
method at 180 minutes, the mean GFRW and GFRV were
77.59  28.89 and 77.92  29.04 ml/min, respectively.
The median paired difference between GFRW and GFRV
was 0.28 (Pct 2.5 ¼ 3.36; Pct 97.5 ¼ 2.17) ml/min.
Concordance within 5% was observed in 94.0% of
subjects. With the SS method at 240 minutes, the mean
GFRW and GFRV were 63.58  24.34 and 63.80  24.42
ml/min, respectively. The median paired difference
between GFRW and GFRV was 0.07 (Pct 2.5 ¼ 3.06;
Pct 97.5 ¼ 1.95) ml/min. Concordance within 5% was
observed in 95.0% of subjects. Restricting the analysis
to subjects with MS available (n ¼ 2941), mGFR by SS
at 180 minutes with GFRW and GFRV were 65.32 
25.40 and 65.58  25.52 ml/min, respectively. The
median paired difference between GFRW and GFRV
was 0.08 (Pct 2.5 ¼ 3.97; Pct 97.5 ¼ 2.48) ml/min,
with a concordance within 5% of 91.0%. The mGFR by
SS at 240 minutes with GFRW and GFRV were 63.09 
24.27 and 63.30  24.35 ml/min, respectively. TheTable 1. Characteristics of patients with concordant versus discordant re
Characteristics Concordant results
MS (n [ 2941) n [ 2842
Age (yr) 54 [40; 64]
Sex (%) 43
BMI (kg/m2) 24.6 [21.5; 28.4]
Weight (kg) 70 [59; 82]
GFR (ml/min) 60 [44; 81]
DGFR (ml/min) –0.03 [–2.67; 1.97]
SS at 180 min (n [ 4488) n [ 4217
Age (y) 56 [48; 62]
Sex (%) 45
BMI (kg/m2) 25.6 [22.5; 28.9]
Weight (kg) 73 [63; 85]
GFR (ml/min) 80 [58; 100]
DGFR (ml/min) –0.25 [–2.59; 1.88]
SS at 240 min (n [ 3018) n [ 2875
Age (yr) 54 [41; 63]
Sex (%) 44
BMI (kg/m2) 24.7 [21.6; 28.6]
Weight (kg) 70 [60; 82]
GFR (ml/min) 62 [47; 81]
DGFR (ml/min) –0.05 [–2.34; 1.68]
The GFR value is the GFR calculated with syringe weighted. DGFR is the difference between
volume. Results are expressed as median [percentile 25; percentile 75], except DGFR, which i
BMI, body mass index; GFR, glomerular filtration rate; MS, multiple-sample; NS, not significan
Kidney International Reports (2021) 6, 2478–2480median paired difference between GFRW and GFRV
was 0.06 (Pct 2.5 ¼ 3.07; Pct 97.5 ¼ 1.97) ml/min,
with a concordance within 5% of 94.9%. Concordance
was thus significantly higher with the MS method than
with the SS at 180 minutes or 240 minutes, and
concordance was higher with SS at 240 minutes than at
180 minutes (all pairwise P values <0.0001).
We compared age, sex, BMI, and GFR levels of
subjects with concordant and discordant GFR results
(GFRW vs. GFRV) in Table 1. Regarding GFR calculated
with the MS method, characteristics of patients were
not different for those with discordant or concordant
results. For the SS methods, subjects with discordant
results were older and had lower GFR levels.
To the best of our knowledge, the impact on GFR
calculations of weighing the syringe (or not) has not
been studied until now. Our results showed a high rate
of concordance between the 2 methods, with a vast
majority of results concordant within 5%, which is a
very stringent criterion. Because of the very large
sample size, the bias between GFRW and GFRV was
statistically significant but was irrelevant from a clin-
ical perspective (<1 ml/min). The impact of weighing
the syringe (or not) seems particularly negligible in MS
methods, with a rate of concordance reaching 97%.
Characteristics of the few subjects with discordant re-
sults were not different from those of subjects with
concordant results, suggesting that discordant results
are probably due to errors or imprecisions in iohexol
injection. Also, the median paired difference betweensults (at 5%)
Discordant results P value
n [ 99
55 [40; 62] NS
43 NS
24.7 [20.9; 28.7] NS
68 [58; 83] NS
59 [43; 75] NS
–3.47 [–13.23; 10.37] <0.0001
n [ 271
60 [49; 71] <0.0001
46 NS
25.9 [22.5; 30.7] NS
73 [62; 85] NS
44 [32; 59] <0.0001
–2.54 [–10.31; 10.06] <0.0001
n [ 143
59 [47; 72] <0.0001
46 NS
25.7 [21.9; 30.2] NS
72 [58; 83] NS
42 [29; 61] <0.0001
–2.16 [–11.00; 9.76] <0.0001
GFR obtained by weighing the syringes and GFR obtained by considering the injected
s expressed as median [percentile 2.5; percentile 97.5].
t; SS, single-sample.
2479
RESEARCH LETTERGFRW and GFRV in subjects with so-called discordant
results remained actually low (Table 1). Of note, if a
criterion of concordance of 10% is retained, only 23 re-
sults (i.e., 0.8%) were discordant. In the SS methods, the
impact of weighing the syringe on the concordance be-
tween GFRW and GFRV becomes smaller with increasing
time-point. Having said that, the concordance with SS
remained very high between GFRW and GFRV (>90%).
Once again, if a concordance within 10% was retained,
discordant results were 1.1% at both times 180 minutes
and 240 minutes, respectively. Of interest, the SS method
at both times 180 minutes and 240 minutes showed
higher discordant results at lower GFR levels (~40 ml/min
in our cohort). This may be explained by the form of the
Jacobsson equation, because, at low GFRs, the iohexol
concentration in the SS remains relatively high, which
increases the relative error in GFR (the denominator in
Jacobsson’s error formula becomes smaller). It must be
noted that in such a low GFR range, a time-point later
than 180 minutes is recommended in SS methods.
The main limitation of the current analysis is that there
is no way to evaluate the absolute impact of errors in
weighing or volume estimation, because there is no
reference. Weighing the syringes is relatively easy and is
performed to overcome the possible errors of using the
theoretical volume. However, the current analysis dem-
onstrates that both strategies are equivalent. In practice,
weighing syringes is important in rare cases in which the
volume of iohexol cannot be fully injected for practical
reasons. Indeed, even if medical records were checked in
patients with discrepancies of more than 5% to verify the
volume of iohexol injected, it remains possible that the
volume effectively injected was different from the volume
defined by the protocol, notably because of difficulties
with venipuncture in some patients. This could probably
explain gross discrepancies between results observed in a
minority of patients.
In this large cohort of subjects with iohexol plasma
clearances, we showed that estimating the volume of
iohexol injected or weighing the syringes and using
iohexol density led to the same GFR results in the vast
majority of subjects.
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Table S1. Different equations used in the analysis
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